Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy

British Journal of Pharmacology

Volumn 130, Issue 7, 2000, Pages 1489-1495

  Watanabe, Kenichi ^a   Ohta, Yoshimi ^a   Nakazawa, Mikio ^b   Higuchi, Hiroshi ^b   Hasegawa, Go ^b   Naito, Makoto ^b   Fuse, Koichi ^b   Ito, Masahiro ^b   Hirono, Satoru ^b   Tanabe, Naohito ^b   Hanawa, Haruo ^b   Kato, Kiminori ^b   Kodama, Makoto ^b   Aizawa, Yoshifusa ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Atrial natriuretic peptide; Carvedilol; Dilated cardiomyopathy; Heart failure; Myocardial fibrosis; Myocarditis; Rat model; blocker

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METHYLCELLULOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RATE; HEART WEIGHT; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033862019     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703450     Document Type: Article

References (39)

1. ANDERSON, J.L., LUTZ, J.R., GILBERT, E.M., SORENSEN, S.G., YANOWITZ, F.G., MENLOVE, R.L. & BARTHOLOMEW, M. (1985). A randomized trial of low-dose β-blockade therapy for idiopathic dilated cardiomyopathy. Am. J. Cardiol., 55, 471-475.
2. BARONE, F.C., NELSON, A.H., OHLSTEIN, E.H., WILLETTE, R.N., SEALEY, J.E., LARAGH, J.H., CAMPBELL, W.G. & FEUERSTEIN, G.Z. (1996). Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J. Pharmacol. Exp. Ther., 279, 948-955.
3. BARONE, F.C., WALLACE, G., CAMPBELL, W.G., NELSON, A.H. & FEUERSTEIN, G.Z. (1998). Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. J. Hypertens., 16, 871-884.
4. BELCH, J.J.F., BUDGES, A.B., SCOTT, N. & CHOPRA, M. (1991). Oxygen free radicals and congestive heart failure. Br. J. Heart J., 65, 245-248.
5. BOHM, M., LARAGH, J.H. & ZEHENDER, M. (1998). From hypertension to heart failure. Berlin: Springer; pp. 177-205.
6. BRIL, A., SLIVJAK, M. & DIMARTINO, M.J. (1992). Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilation properties, in anaesthetized minipigs: comparison with propranolol. Cardiovasc. Res., 26, 518-525.
7. BRISTOW, M.R., GILBERT, E.M., ABRAHAM, W.T., ADAMS, K.F., FOWLER, M.B., HERSHBERGER, R.E., KUBO, S.H., NARAHARA, K.A., INGERSOLL, H., KRUEGER, S., YOUNG, S. & SHUSTERMAN, N. (1996). Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation, 94, 2807-2816.
8. BROOKS, D.P., SHORT, B.G., CYRONAK, M.J., CONTINO, L.C., DICRISTO, M., WANG, Y.X. & RUFFOLO, Jr. R.R. (1993). Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br. J. Pharmacol., 109, 581-586.
9. BURNETT, J.C. Jr, KAO, P.C., HU, D.C., HESER, D.W., HEUBLEIN, D., GRANGER, J.P., OPGENORTH, T.J. & REEDER, G.S. (1986). Atrial natriuretic peptide elevation in congestive heart failure in the human. Science, 231, 1145-1147.
10. 2+ current in rabbit ventricular myocytes. Eur. J. Pharmacol., 376, 189-201.
11. COHN, J.N., FOWLER, M.B., BRISTOW, M.R., COLUCCI, W.S., GILBERT, E.M., KINHAL, V., KRUEGER, S.K., LEJEMTEL, T., NARAHARA, K.A., PACKET, M., YOUNG, S.T., HOLCSLAW, T.L. & LUKAS, M.A. (1997). Safety and efficacy of carvedilol in severe heart failure. J. Card. Failure, 3, 173-179.
12. DAVIDOFF, R., PALACIOS, I., SOUTHERN, J., FALLON, J.T., NEWELL, J. & DEC, G.W. (1991). Giant cell versus lymphocytic myocarditis: a comparison of their clinical features and long-term outcomes. Circulation, 83, 953-961.
13. DEC, G.W., PALACIOS, I.F., FALLON, J.T., ARETZ, H.T., MILLS, J., LEE, D.C.S. & JOHNSON, R.A. (1985). Acute myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome. N. Eng. J. Med., 312, 885-890.
14. FEUERSTEIN, G.Z. & RUFFOLO, R.R. (1995). Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J., 16, (suppl F), 38-42.
15. FEUERSTEIN, G.Z. & YUE, T.L. (1994). A potent antioxidant, SB209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Eur. J. Pharmacol., 48, 385-391.
16. GILBERT, E.M., OLSEN, S.L., RENLUND, D.G. & BRISTOW, M.R. (1993). β-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am. J. Cardiol., 71, 23C-29C.
17. HANAWA, H., KODAMA, M., ZHANG, S., IZUMI, T. & SHIBATA, A. (1992). An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. Clin. Immuno. Immunopath., 62, 321-326.
18. HIRATA, Y., ISHII, M., MATSUOKA, H., SUGIMOTO, T., IIZUKA, M., UCHIDA, Y., SERIZAWA, T., SATO, H., KOHMOTO, O., MOCHIZUKI, T., SUGIMOTO, T., MIYATA, A., KANGAWA, K. & MATSUO, H. (1987). Plasma concentrations of α-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease. Am. Heart J., 113, 1463-1469.
19. HIRONO, S., ISLAM, M.O., NAKAZAWA, M., YOSHIDA, Y., KODAMA, M., SHIBATA, A., IZUMI, T. & IMAI, S. (1997). Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. Circ. Res., 80, 11-20.
20. KATO, K., NAKAZAWA, M., MASANI, F., IZUMI, T., SHIBATA, A. & IMAI, S. (1995). Ethanol ingestion on allylamine-induced experimental subendocardial fibrosis. Alcohol, 12, 233-239.
21. KAWADA, T., ISHIBASHI, T., NAKAZAWA, M., SATOH, S. & IMAI, D. (1990). Adrenoceptor-blocking activity and cardiohemodynamic effects of carvedilol in animals. J. Cardiovasc. Pharmacol., 16, 147-153.
22. KLINGEL, K., HOHNENADL, C., CANU, A., ALBRECHT, M., SEEMANN, M., MALL, G. & KANDOLF, R. (1992). Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl. Acad. Sci. U.S.A., 89, 314-318.
23. KODAMA, M., HANAWA, H., SAEKI, M., HOSONO, H., INOMATA, T., SUZUKI, K. & SHIBATA, A. (1994). Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ. Res., 75, 278-284.
24. KODAMA, M., MATSUMOTO, Y., FUJIWARA, M., MASANI, F., IZUMI, T. & SHIBATA, A. (1991). A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin. Immunol. Immunopathol., 57, 250-262.
25. MALLORY, F.B. (1936). The anilin blue collagen stain. Stain Technol., 11, 101-109.
26. MATSUMORI, A. & KAWAI, C. (1982). An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation, 66, 355-360.
27. NICHOLS, A.J., GELLAI, M. & RUFFOLO Jr, R.R. (1991). Studies on the mechanism of arterial vasodilation produced the novel antihypertensive agent, carvedilol. Fundam. Clin. Pharmacol., 5, 25-38.
28. OHLSTEIN, E.H., DOUGLAS, S.A., SUNG, C.P., YUE, T.L., LOUDEN, C., ARLETH, A., POSTE, G., RUFFOLO, R.R. & FEUERSTEIN, G.Z. (1993). Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc. Natl. Acad. Sci. U.S.A., 90, 6189-6193.
29. PACKER, M., BRISTOW, M.R., COHN, J.N., COLUCCI, W.S., FOWLER, M.B., GILBERT, E.M. & SHUSTERMAN, N.H. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med., 334, 1349-1397.
30. PATEL, M.K., CHAN, P., BETTERIDGE, L.J., SCHACHTER, M. & SEVER, P.S. (1995). Inhibition of human vascular smooth muscle cell proliferation by novel multi-action antihypertensive agent carvedilol. J. Cardiovasc. Pharmacol., 25, 652-657.
31. ROBERTS, W.C., SIEGEL, R.J. & MCMANUS, B.M. (1987). Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am. J. Cardiol., 60, 1340-1355.
32. RUFFOLO, R.R., BOYLE, D.A., BROOKS, D.P., FEUERSTEIN, G.Z., VENUTI, R.P., LUKAS, M.A. & POSTE, G. (1992). Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovasc. Drug. Rev., 10, 127-157.
33. RUFFOLO Jr, R.R., GELLAI, M., HIEBLE, J.P., WILLETTE, R.N. & NICHOLS, A.J. (1990). The pharmacology of carvedilol. Eur. J. Clin. Pharmacol., 38, S82-S88.
34. SOBOTKA, P.A., BROTTMAN, M.D., WEITZ, Z., BIRNBAUM, A.J., STOSEY, J.L. & ZARLING, E.J. (1993). Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic. Biol. Med., 14, 643-647.
35. SUNG, C.P., ARLETH, A.J. & OHLSTEIN, E.H. (1993). Carvedilol inhibits vascular smooth muscle cell proliferation. J. Cardiovasc. Pharmacol., 21, 221-227.
36. TALIERCIO, C.P., SEWARD, J.B., DRISCOLL, D.J., FISHER, L.D., GERSH, B.J. & TAJIK, A.J. (1985). Idiopathic dilated cardiomyopathy in the young: clinical profile and natural history. J. Am. Coll. Cardiol., 6, 1126-1131.
37. YUE, T.L., CHENG, H.Y., LYSKO, P.G., MCKENNA, P.J., FEUERSTEIN, R., GU, J.L., LYSKO, K.A., DAVIS, L.L. & FEUERSTEIN, G. (1992). Carvedilol, a new vasodilator and β-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther., 263, 92-98.
38. YUE, T.L., MCKENNA, P.J., LYSKO, P.G., GU, J.L., LYSKO, K.A., RUFFOLO, Jr R.R. & FEUERSTEIN, G.Z. (1994). SB211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur. J. Pharmacol., 251, 237-243.
39. YUE, T.L., WANG, X., GU, J.L., RUFFOLO, Jr R.R. & FEUERSTEIN, G.Z. (1995). Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J. Pharmacol. Exp. Ther., 273, 1442-1449.